You are here: Industry Insights > cystic fibrosis

News List

Roche acquires Enterprise Therapeutics’ potentiator portfolio pharmaceutical-technology
October 10, 2020
Roche Group has acquired biopharma firm Enterprise Therapeutics’ TMEM16A potentiator portfolio, developed by its member Genentech.
Potential Cystic Fibrosis Treatment Does Not Meet Primary Endpoint americanpharmaceuticalreview
October 10, 2020
Corbus Pharmaceuticals announced topline results from its 28-week Phase 2b study of lenabasum in patients with cystic fibrosis (CF).
Moderna and Vertex partner on gene-editing therapies for cystic fibrosis pharmaceutical-technology
September 18, 2020
Moderna has teamed up with Vertex Pharmaceuticals to identify and develop lipid nanoparticles (LNPs) and messenger RNAs (mRNAs) for the delivery of gene-editing therapies to treat cystic fibrosis (CF).
Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS europeanpharmaceuticalreview
August 27, 2020
The European Commission and European Medicines Agency have approved the triple combination Kaftrio for use in certain cystic fibrosis patients, triggering the drug to be accessible on the UK’s National Health Service.
EC approves Vertex’s Kaftrio plus ivacaftor for cystic fibrosis patients pharmaceutical-technology
August 25, 2020
Vertex Pharmaceuticals has secured approval from the European Commission (EC) for the use of Kaftrio (ivacaftor / tezacaftor / elexacaftor) in combination with ivacaftor for the treatment of cystic fibrosis (CF).
CHMP recommends cystic fibrosis treatment Kaftrio is granted marketing authorisation europeanpharmaceuticalreview
July 03, 2020
The European Medicines Agency’s human medicines committee (CHMP) said the treatment would offer a therapeutic option for certain cystic fibrosis phenotypes that are currently untreatable.
Network of channels inside bacterial communities can help kill bacteria faster: Study expresspharma
June 22, 2020
This could change the way that pharma companies approach treatment strategies and help design new methods for delivering drugs to destroy the biofilm ‘fortresses’ and killing the bacteria within it, claim researchers.
EU expands reach of Vertex' CF drug Kalydeco pharmatimes
June 11, 2020
EU regulators have expanded the treatment scope of Vertex' Kalydeco (ivacaftor) to include a new subset of young patients with cystic fibrosis (CF).
Arrowhead Pharmaceuticals files for regulatory clearance to begin phase 1/2a study of ARO-ENaC for treatment of cystic fibrosis pharmaceutical-business-review
April 15, 2020
Arrowhead Pharmaceuticals has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-ENaC.
EC approves expanded indication for cystic fibrosis treatment europeanpharmaceuticalreview
December 12, 2019
The European Commission has approved the label extension for KALYDECO® (ivacaftor) to include the treatment of infants with cystic fibrosis between six and 12 months old.

Previous page 1 2 3 4 5 6 Next page